Belvarafenib

type II RAF dimer kinase inhibitor

oral 450 mg BID, Ph. II in BRAF/RAS cancers

demonstrated activity in NRAS-mut. tumors

Nature, May 5, 2021

Genentech, CA / Hanmi Pharma, KR

The Hanmi/Genentech type II RAF kinase inhibitor, belvarafenib, is a potent and selective inhibitor of RAF dimers. GNE-9815 was covered last month, which was used to validate the biology supporting clinical…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.